Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes

British Journal of Pharmacology

Volumn 164, Issue 2 B, 2011, Pages 820-827

  Shukla, Anshuman ^a   Singh, Bhupinder ^a   Katare, O P ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

immune tolerance; M cells; mucosal immunization; Peyer's patches; sIgA antibody; vaccination

Indexed keywords

DIPHTHERIA TOXOID; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NANOBILOSOME; NANOCARRIER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIPHTHERIA; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; MUCUS SECRETION; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, BACTERIAL; CHEMISTRY, PHARMACEUTICAL; DIPHTHERIA; DIPHTHERIA TOXOID; DRUG STABILITY; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NANOCONJUGATES; VACCINATION;

EID: 80052238985     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01452.x     Document Type: Article

References (35)

1. Alpar HO, Eyles JE, Williamson ED, Somavarapu S, (2001). Intranasal vaccination against plague, tetanus and diphtheria. Adv Drug Deliv Rev 51: 173-201. (Pubitemid 32763081)
2. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE, (2010). Chitosan-based delivery systems for protein therapeutics and antigens. Adv Drug Deliver Rev 62: 59-82.
3. Chen H, Torchilin V, Langer R, (1996). Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm Res 13: 1378-1383. (Pubitemid 26344985)
4. Clark MA, Jepson MA, Hirst BH, (2001). Exploiting M cells for drug and vaccine delivery. Adv Drug Deliver Rev 50: 81-106. (Pubitemid 32727278)
5. Clements CJ, Griffiths E, (2002). The global impact of vaccines containing aluminium adjuvants. Vaccine 20 (Suppl. 3): S24-S33. (Pubitemid 34607672)
6. Conacher M, Alexander J, Brewer JM, (2001). Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine 19: 2965-2974. (Pubitemid 32244290)
7. Dertzbaugh MT, Elson CO, (1993). Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect Immun 61: 48-55. (Pubitemid 23015398)
8. DiBiase MD, Morrel EM, (1997). Oral delivery of microencapsulated proteins. Pharm Biotechnol 10: 255-288.
9. Dubois B, Goubier A, Joubert G, Kaiserlian D, (2005). Oral tolerance and regulation of mucosal immunity. Cell Mol Life Sci 62: 1322-1332. (Pubitemid 40853819)
10. Elson CO, Ealding W, Lefkowitz J, (1984). A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions. J Immunol Methods 67: 101-108. (Pubitemid 14156720)
11. Eriksson K, Holmgren J, (2002). Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14: 666-672.
12. Fromen-Romano C, Drevet P, Robert A, Menez A, Leonetti M, (1999). Recombinant Staphylococcus strains as live vectors for the induction of neutralizing anti-diphtheria t oxin antisera. Infect Immun 67: 5007-5011. (Pubitemid 29455267)
13. Fry DW, White JC, Goldman ID, (1978). Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem 90: 809-815. (Pubitemid 9087732)
14. Galazka A, (2000). The changing epidemiology of diphtheria in the vaccine era. J Infect Dis 181 (Suppl. 1): S2-S9. (Pubitemid 30130098)
15. Gandon S, Mackinnon MJ, Nee S, Read AF, (2001). Imperfect vaccines and the evolution of pathogen virulence. Nature 414: 751-756. (Pubitemid 34000772)
16. George RC, Beloborodov VB, Efstratiou A, (1995). Diphtheria in the 1990s: return of an old adversary. Clin Microbiol Infect 1: 139-145.
17. Holmgren J, Czerkinsky C, (2005). Mucosal immunity and vaccines. Nat Med 11 (4 Suppl.): S45-S53. (Pubitemid 40562303)
18. Jepson MA, Clark MA, Hirst BH, (2004). M cell targeting by lectins: a strategy for mucosal vaccination and drug delivery. Adv Drug Deliver Rev 56: 511-525. (Pubitemid 38210420)
19. Kelly C, Efstratiou A, (2003). Seventh International Meeting of the European Laboratory Working Group on Diphtheria. Euro Surveill: Vienna, pp. 189-195.
20. Kuby J, (2007). Immunology. 5th edn. W. H. Freeman and Co.: New York.
21. Lehr CM, (1994). Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 11: 119-160.
22. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE, (2003). Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21: 1400-1408. (Pubitemid 36263181)
23. Mann JFS, Ferro VA, Mullen AB, Tetley L, Mullen M, Carter KC, et al,. (2004). Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin. Vaccine 22: 2425-2429. (Pubitemid 38757340)
24. Martin-Munoz MF, Pereira MJ, Posadas S, Sanchez-Sabate E, Blanca M, Alvarez J, (2002). Anaphylactic reaction to diphtheria-tetanus vaccine in a child: specific IgE/IgG determinations and cross-reactivity studies. Vaccine 20: 3409-3412. (Pubitemid 35245824)
25. McClean S, Prosser E, Meehan E, O'Malley D, Clarke N, Ramtoola Z, et al,. (1998). Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur J Pharm Sci 6: 153-163. (Pubitemid 28164286)
26. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H, (1992). The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10: 75-88.
27. Mowat AM, (2003). Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 3: 331-341. (Pubitemid 37328685)
28. Neutra MR, Kraehenbuhl J, (1996). Antigen uptake by M cells for effective mucosal vaccines. In:, Kiyono H, Ogra PL, McGhee JR, (eds.). Mucosal Vaccines. Academic Press: San Diego, CA, pp. 41-55.
29. Schroder U, Svenson SB, (1999). Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Vaccine 17: 2096-2103. (Pubitemid 29172383)
30. Shalaby WSW, (1995). Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies. Clin Immunol Immunopathol 74: 127-134.
31. Shukla A, Khatri K, Gupta PN, Goyal AK, Mehta A, Vyas SP, (2008). Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes). J Pharm Pharm Sci 11: 59-66.
32. Shukla A, Katare OP, Singh B, Vyas SP, (2010). M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes. Int J Pharm 385: 47-52.
33. Werle M, Takeuchi H, Bernkop-Schnurch A, (2009). Modified chitosans for oral drug delivery. J Pharm Sci 98: 1643-1656.
34. WHO, UNICEF, World Bank (2009). State of the World's Vaccines and Immunization. World Health Organization: Geneva.
35. Worbs T, Bode U, Yan S, Hoffmann MW, Hintzen G, Bernhardt G, et al,. (2006). Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. J Exp Med 203: 519-527.